propoxy]phenyl]-5-trifluoromethyl-1,2,4-oxadiazole (IFO), design ed to be a novel selective inhibitor of monoamine oxidase (MAO), showed highly selective inhibition for type-B (MAO-B); its IC50 was approximately > 200 pM and 30 nM for type-A (MAO-A) and MAO-B, respectively, in the standard assay using mitochondrial preparations from rat brain or liver. The in vitro MAO-B inhibition by IFO was time-independent, non-competitive and tight-binding; and furthermore, in the presence of sodium cholate its inhibition was not tight-binding and was reversible. Oral administration of IFO (0.5 -100 mg/kg) produced a dose-dependent MAO-B inhibition in mouse brain; its ED50 (p.o., 1 hr) was 1.6 mg/kg, while L-deprenyl inhibited the enzyme with the ED50 of approximately 8.0 mg/kg. The ED50 for MAO-A was > 100 mg/kg for either IFO and L-deprenyl. The MAO inhibitive effect of IFO in mouse liver was the same as that in the brain, but that of L-deprenyl in mouse liver was different from that in the brain as shown by the ED50 values of 35 mg/kg and 0.6 mg/kg for MAO-A and MAO-B, respectively. In mice, IFO increased the striatal concentrations of 2-phenylethylamine (2-PEA) and showed almost the same protective efficacy as L-deprenyl against the lethality and striatal dopamine (DA) depletion induced by 1 methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). These results indicate that IFO appears to be a potent inhibitor of MAO-B in mouse brain.
Biogenic endogenous and exogenous monoamines are inactivated by monoamine oxidase (MAO: EC 1.4.3.4). MAO exists in two functional isoenzymic forms termed MAO-A and MAO-B, which are differentiated by their selectivity towards various substrates and inhibitors. The MAO-A isoenzyme preferentially oxidizes 5-hydro xytryptamine (5-HT) and norepinephrine, whereas the MAO-B isoenzyme prefers trace amines such as 2 phenylethylamine (2-PEA) and octopamine. Dopamine (DA) and tryptamine seem to be oxidized by both MAO A and MAO-B. Selective inhibitors of the two different forms of MAO have been discovered (e.g., clorgyline for MAO-A, L-deprenyl for MAO-B), and the enzymes show different pharmacological profiles (1) . When a non-selec tive inhibitor is used, one must consider the hazards of its combination with a variety of foods and drugs, and the use of a MAO-A inhibitor has also been frequency accom panied by a number of other serious side effects based on the activation of the 5-HTergic system (2) . The selective inhibitors of MAO-B, however, being free from these side effects (2, 3) , are considered to be safe drugs for human use. Treatment with MAO-B inhibitor is thought to be suitable for the treatment of Parkinson's disease (PD) because nigrostriatal DA is thought to be inactivated predominantly by MAO-B in humans (4) and it is remark ably deficient in parkinsonian patients. Additionally, the turnover of DA by MAO increases in the surviving nigro striatal neurons of parkinsonian patients, which conse quently results in an increased formation of hydrogen peroxide that may lead to neuronal degeneration (5, 6) . Recently, it has been found that platelet MAO-B activity is significantly raised in untreated parkinsonians with age matched controls, and that the level of the endogenous MAO-B inhibitor isatin in their cerebrospinal fluid was decreased compared to that in the controls (7) . Moreover, it has been found that endogenous 2-PEA may modulate the DAergic transmission in nigrostriatal neurons and that this modulation is enhanced by the increased striatal concentration of 2-PEA induced by L-deprenyl (8) . There fore, DA-turnover repression and optimum stimulation of DA neurons in parkinsonian nigrostriata are required, and the regulation of MAO-B activity with some selective inhibitor may prove to be a suitable medical treatment to satisfy this requirement. The usefulness of L-deprenyl for suppressing the progression of this disease has already been demonstrated. It has been reported that the L-dopa (levodopa) treatment combined with L-deprenyl has reduced the side effects and prolonged parkinsonian life span as compared to treatment with levodopa alone (9) . A potent and reversible MAO-B inhibitor would provide a safe adjuvant that is devoid of the hazards of unwanted side effects. However, most of the currently available po tent MAO-B inhibitors, like L-deprenyl, are irreversible and long-lasting.
The present report is about the pharmacological evalu ation of 3-[4-[3-(1H-imidazol-1-yl)propoxy]phenyl]-5 trifluoromethyl-1,2,4-oxadiazole (IFO) (Fig. 1) , a new potent, selective and reversible MAO-B inhibitor. We describe the characteristics of the inhibitory effect of IFO on MAO-B activity in vitro and in vivo, and the protec tive efficacy of this compound against the DAergic neuro toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse (10). 
MATERIALS AND METHODS

MAO activity determinations
For the in vitro experiments, whole brains or livers were removed from male Sprague-Dawley rats weighing 230 to 400 g and homogenized in cold 0.25 M sucrose. The mitochondrial fraction was obtained by the differen tial centrifugation technique of Yasunobu and Gomes (11) to yield a kynuramine-oxidative activity of 130 nmol/ml/min and stored at -40 C until used. The kynuramine-oxidative activity was determined by measur ing oxygen consumption with a polarographic electrode under the same condition in the method of Tipton and Dawson (12), using 0.3 mM kynuramine as substrate.
The activities of two different forms of MAO were determined by measuring oxygen consumption as stated above using 5-HT and benzylamine (BZ) as the selective substrates for MAO-A and MAO-B, respectively. In the standard assay, mitochondrial protein (0.54 mg/ml) was preincubated with various amounts of IFO at 371C for 4 min in a reaction chamber with an oxygen electrode. Then the substrate (500 pM for 5-HT or BZ) was added to the reaction mixture, and its oxygen consumption rate was measured.
In the ex vivo MAO determination, mice were sacri ficed at the indicated time, and then the isolated tissues were homogenized in 50 mM potassium phosphate buffer, pH 7.4. MAO-A activity was determined with 5-HT as the substrate by the fluorometric assay method of Hidaka et al. (13) . MAO-B activity was determined with kynuramine as the substrate according to the fluorometric method of Kraml (14) under the inhibition of MAO-A activity by 1 pM clorgyline.
Monoamine and its metabolites determinations
After decapitation of the mice, the brain striata were quickly removed, frozen on dry-ice and stored at 801C until used. Striatal DA, its metabolites 3,4-dihydroxy phenylacetic acid (DOPAC), homovanillic acid (HVA) and 3-methoxytyramine (3-MT) were determined by high-performance liquid chromatography with electro chemical detection as follows: Striata were homogenized in 0.2 ml of 0.1 M perchloric acid containing 3,4-dihy droxybenzylamine as an internal standard, 1 mM diso dium EDTA, and 1 mg/ml sodium bisulfite. After stand ing for 20 min in ice cold water, the homogenate was cen trifuged. The supernatant was eluted in a 5 pm Capcell ODS® (Shiseido, Tokyo) column of 4 mm x 250 mm with a mobile phase (pH 3.2) consisting of 4% acetonitrile, 75 mM sodium nitrate, 75 mM citric acid, 50 mM sodium acetate, 4 mM di-n-butylamine, 1 mM sodium octylsulfate and 0.15 mM disodium EDTA at a flow rate of 0.7 ml/min. 2-PEA only was determined by gas chromato graphy of the pentafluorobenzoyl derivative with electron capture detection according to the method of Reynolds et al. (15) after extraction with 0.2 ml of 0.1 M perchloric acid containing 3-phenylpropylamine as an internal standard.
Drug treatments
Male C57 black mice, 5 to 6-week-old, obtained from Clea Japan, Inc. (Tokyo) were used for in vivo and ex vivo experiments.
Details for each experiment are described in the legend for each figure and table. MPTP hydrochloride was dissolved in saline solution and ad ministered by s.c. injection. IFO suspended in 0.5% methylcellulose solution was administered orally at vari ous doses. At the indicated time, mice were decapitated and their whole brains (or striata) and livers were re moved quickly and frozen on dry ice, and they were stored at -80'C until used.
Drugs
IFO was synthesized at our company. Fig. 2 . Lineweaver-Burk plots on the MAO inhibitory activity of IFO in rat liver mitochondrial fraction in the absence of (A) and in the presence of (B) sodium cholate. The mitochondrial protein (0.54 mg/ml) was preincubated with (0) or without (0) IFO for 5 min at 371C, and the initial velocity of MAO-B activity was determined by measuring oxygen consumption at varying concentrations of BZ. B: sodium cholate was present at a concentration of 1010 in the preincubation and the activity determina tion.
RESULTS
Inhibition of MAO by IFO in vitro
In rat brain and liver mitochondrial preparations, the concentration of IFO required to inhibit the oxidation of BZ was lower than when it acted in the oxidation of 5-HT (Table 1) . L-Deprenyl also potently inhibited MAO-B activity in these mitochondrial preparations, but did not inhibit more selectively than IFO. Under the different periods of preincubation, the IC50 value of IFO was not al tered when BZ was used as a substrate, whereas that of L deprenyl altered time-dependently under the same condi tions. MAO activity in the mixture of IFO and a liver mitochondrial fraction did not recover after dialysis against (or washing with) potassium phosphate buffer, but recovered fully after dialysis in the presence of so dium cholate (not shown). The MAO-B inhibition activ ity of IFO in the mitochondrial preparation was non-com petitive toward BZ in either the presence (Fig. 2B) or ab sence ( Fig. 2A) of sodium cholate. In the absence of so dium cholate, the Henderson plot gave parallel lines sup porting tight-binding behavior (16) (Fig. 3) (Fig. 3 ) was 33 nM, and Fig. 2A shows the same value in the second ary plot of the slopes of the line against IFO concentra tions. On the other hand, the line-separation depending on the protein concentration, although there was no pre cise line-crossing at the origin of the axes, was not ob tained in the presence of sodium cholate (Fig. 3) . The presence of sodium cholate created an IC50 value of 49 nM at either protein concentration. The K; value in the presence of sodium cholate was 90-180 nM in the Lineweaver-Burk and Henderson plots, so in the presence of sodium cholate, a higher concentration of IFO was re quired to inhibit MAO-B. Table 2 . L-Deprenyl inhibited selec tively MAO-B in the brain and liver; however, its inhibi tory activity for MAO-A and -B in the liver was larger than that in the brain. When mice were administered a single dose of IFO (5 mg/kg, p.o., a dose 3 times higher than the ED50 for MAO-B activity), the MAO-B inhibitory effect continued for about 8 hr with little influence on the MAO-A activity in the brain and liver (Fig. 4) . The oral administration (0.5 30 mg/kg) of IFO to mice produced a dose-dependent increase in the striatal concentration of 2-PEA (Fig. 5 ).
Protective effect of IFO against the dopaminergic neuro toxicity of MPTP The protective effect against MPTP toxicity was tested in mice pretreated with some doses of IFO and L-dep renyl. Table 3 shows that IFO produced protection against an acute lethal toxicity of MPTP (100 mg/kg, s.c., a dose sufficient to kill all mice used in the present experi ment). Its effective dose was about the same as the ED50 value for brain MAO-B activity in Table 2 . The dose of IFO required to increase the survival of the mice tended to be smaller than that of L-deprenyl in relation to their ED50 for MAO-B activity. At 5 mg/kg, IFO as well as L-dep renyl completely protected the mice against MPTP lethal toxicity and protected against the depletion of DA and its metabolites, except for 3-MT, in mice brain striata induced by repeated subcutaneous injection of MPTP, as shown in Table 4 . The metabolite ratio (DOPAC+HVA)/DA showed little alteration with either inhibitor in MPTP treated mice, and 3-MT/DA was recovered to the normal value by either inhibitor in spite of its increase by MPTP treatment. 
DISCUSSION
The present study demonstrated that IFO inhibits selec tively MAO-B in rodent brain and liver in vitro and in vivo. IFO produced time-independent inhibition, but its binding to the mitochondrial fraction was quite tight with no change after dialysis (or washing) with buffer. If MAO-B catalyzed the conversion of IFO in the same man ner as its conversion of other irreversible inhibitors (17) , which have been divided into four chemical types: sub stituted hydrazine, cyclopropylamine, propargylamine and allylamine derivatives, IFO and its product would covalently bind to the active site of this enzyme (17) . However, covalent binding is not supported by the fact that the tight binding behavior of IFO, as shown in the Henderson plot (16), disappears in the presence of so dium cholate, which causes the inhibitor to dissociate from the enzyme. Therefore, it is considered that the hydropho bic property of IFO is important for its MAO-B inhibi tory activity. Yagi and Naoi (18) reported that soluble MAO-containing apoenzyme, partially purified and ob tained after removal of lipids by a surfactant, was in creased by dissociable flavin adenine dinucleotide (FAD), and the dissociation constant of FAD was also influenced by phospholipids. IFO may influence the adherence of free FAD and lipids to the enzyme without formation of a covalent adduct. Table 4 .
Effect of IFO and L-deprenyl on DA, its metabolites and metabolite/DA ratios in MPTP-treated mice striata
The reversibility of IFO was supported by its short lasting activity: its duration of activity was 6-8 hr in the ex vivo experiment for mouse brain MAO-B inhibition and in our preliminary in vivo experiment for striatal 2-PEA concentration, at a single dose of 5 mg/kg, p.o. However, the characteristics of IFO do not seem to reflect its in vitro tight binding behavior. Considering this dis parity, one must determine if IFO may be carried away from the tissue or if it is possibly metabolized in vivo. The reversibility of IFO may be a unique feature as compared to the characteristics of known reversible and irreversible MAO inhibitors (1, 17) .
MAO inhibition by IFO was virtually equipotent in the brain and liver after oral administration in mice; on the other hand, L-deprenyl inhibited liver MAO-B much more potently than the brain enzyme in mice. IFO was not much more potent than L-deprenyl with sufficient preincu bation in the in vitro experiment, but was virtually equipo tent to L-deprenyl in the inhibition of mouse brain MAO B in vivo. In this point, between L-deprenyl and IFO, the in vitro inhibition data (in Table 1 ) for the brain and liver MAO fractions disagreed with the ex vivo inhibition data (in Table 2 ) in mouse brain and liver after oral administra tion. Accordingly, a possible reason for this is that there may be differences in the manners by which these com pounds are translocated into/from the tissues.
The protection by L-deprenyl against MPTP lethality in mice has been reported (19) , and IFO tended to prevent the neurotoxic effects of MPTP as shown in Table 3 . This result shows that IFO protects against the acute lethality of MPTP in mice and against the marked depletion in striatal DA and its metabolites at a dose similar to that of L-deprenyl in mice. Moreover, even though the metabolite ratio should be increased by the metabolite releasing by MPTP (20) , MAO-B inhibition by IFO and L-deprenyl in the metabolism of DA to DOPAC and HVA seemed to be so effective that the recovery from the abnormal (DOPAC + HVA)/DA ratio to the normal one was repressed in MPTP-treated mice. In normal mice, we recognized the ineffectiveness of IFO contrary to the effec tiveness of L-deprenyl in metabolite ratio, which might be due to differences between these compounds with respect to their duration of action and selectivity towards both MAO forms that oxidize DA well. The effectiveness of L deprenyl is thought to be due to the MAO-A inhibition effect since MAO-B is not involved in the majority of DA metabolic processes in DA neurons in rodents (21) (22) (23) . In spite of its ineffectiveness on the metabolite ratio, IFO showed protective efficacy against MPTP toxicity, suggest ing that the time of its effectiveness is thought to sufficient ly cover the time required for the disappearance of MPTP from the mouse brain (20, 24) and that MPTP is convert ed selectively to a toxic metabolite by MAO-B in the brain (25) . Accordingly, the effectiveness of IFO is considered to be due to its blockage of the conversion of MPTP to the toxic metabolite through the inhibition of MAO-B in the mouse brain.
Most of the early symptoms of PD patients derive con siderable benefit from levodopa treatment, but their DA neuronal output pathways from the striatum, although these are spared (26) , are considered to be gradually de generated by oxidative stress associated with the increased DA turnover by its repeated treatment (6) . The available period of PD-therapy will be extended if the onset of levodopa-treatment in patients with early symptoms is deferred by another treatment of stimulating DAergic neu rotransmission and if the levodopa-resistance is prevented by a habitual lower dose of levodopa suported by a new adjuvant. It is possible that these stimulation and support ing strategies will be achieved by DA-tunover inhibition. MAO-B inhibition by IFO increased the striatal 2-PEA concentration in mice. In the human brain, striatal DA is oxidized preferentially by MAO-B (4), so that the 2-PEA increasing efficacy of IFO may affect the DAergic trans mission. Accordingly, if we make another attempt to study the effect of IFO in an animal model, we should use the PD model as animal response to levodopa.
